NASDAQ : FSGS

First Trust SMID Growth Strength ETF

$32.945 USD

$0.5 (1.54%)

Volume
7.47K
Average Volume
2.46K
Market Capitalization
$31.3M
P/E Ratio
Dividend Yield
%
Price Target
Year High
$33.00
Year Low
$28.35
Day High
Day Low
Payout Ratio
Current Ratio
Company Overview

NASDAQ

None

Asset Management

Financial Services

FSGS

N/A

US

USD

1-800-621-1675

33738R746

N/A

Liquidity Metrics

Sales & Valuation

-$

Profitability

-$

%

%

%

%

P/E Metrics

Analyst Price Target & Rating

N/A

0/5

0 Analysts

%

Financial Health Scores

No financial score data available.

Key Metrics (TTM)

No key metrics data available.

Company Executives

No executive data available.

Poll Results

No votes yet today — be the first to share your view!

About First Trust SMID Growth Strength ETF (NASDAQ:FSGS) Stock

The First Trust SMID Growth Strength ETF (the "Fund") aims to deliver investment performance that broadly matches the price movements and income generation (before accounting for the Fund's own fees and expenses) of an equity benchmark, specifically The SMID Growth Strength Index (the "Index"). Ordinarily, the Fund will allocate a minimum of 80% of its net assets (which may include funds borrowed for investment purposes) to the securities that constitute this Index. ...

Everest Medicines Announces Close of Exclusive Licensing Agreement with Travere Therapeutics for Civorebrutinib

2026-07-08 01:00:00

HONG KONG, July 8, 2026 - (ACN Newswire) - Everest Medicines (HKEX 1952.HK) announced the closing of its previously announced exclusive licensing and collaborat

Everest Medicines Enters into Exclusive Licensing Agreement with Travere Therapeutics for Civorebrutinib a Potential Best-in-Class BTK Inhibitor for Rare Kidney Diseases, Driving Value Conversion

2026-06-04 00:00:00

HONG KONG, June 4, 2026 - (ACN Newswire) - Everest Medicines (HKEX 1952.HK) announced that it has entered into an exclusive licensing and collaboration agreemen

Travere Therapeutics Enters Into Exclusive Licensing Agreement with Everest Medicines for Civorebrutinib a Potential Best-in-Class BTK Inhibitor for Rare Kidney Diseases

2026-06-02 08:00:00

Travere Therapeutics, Inc., (Nasdaq: TVTX) today announced that it has entered into an exclusive licensing and collaboration agreement with Everest Medicines f

Frequently Asked Questions

What is the current First Trust SMID Growth Strength ETF (FSGS) stock price?

First Trust SMID Growth Strength ETF(NASDAQ:FSGS) stock price is $32.945 in the last trading session. During the trading session, FSGS stock reached the peak price of $32.9981 while $28.35 was the lowest point it dropped to. The percentage change in FSGS stock occurred in the recent session was 1.54% while the dollar amount for the price change in FSGS stock was $0.5.

FSGS's industry and sector of operation?

The NASDAQ listed FSGS is part of Asset Management industry that operates in the broader Financial Services sector.

Who are the executives of FSGS?

|
|
|
|
|

How many employees does FSGS have?

Number of FSGS employees currently stands at None. FSGS operates from 120 East Liberty Drive, Suite 400, Wheaton, IL 60187, US.

Link for FSGS official website?

How do I contact FSGS?

FSGS could be contacted at phone #1-800-621-1675 and can also be accessed through its website. FSGS operates from 120 East Liberty Drive, Suite 400, Wheaton, IL 60187, US.

How many shares of FSGS are traded daily?

The average number of FSGS shares traded daily for last 3 months was 2.46K.

What is the market cap of FSGS currently?

The market value of FSGS currently stands at $31.3M with its latest stock price at $32.945